Former Vice President Joe Biden was among those who were recognized for improving the lives of patients with gastrointestinal cancer at the Second Annual Luminary Awards, hosted by the Ruesch Center and OncLive.
At a panel discussion on innovation and challenges in clinical research, panelist discussed difficulties related to planning clinical trials for patients with rare tumor types within the existing paradigm.
OncLive® and The Ruesch Center, the founding partners of the Luminary Awards in GI Cancers, congratulate the 2018 honorees recognized at the Second Annual Luminary Awards ceremony, which was held Thursday, Nov. 29 in Washington, D.C.
At the 2nd Annual Luminary Awards, hosted by OncLive and The Ruesch Center for the Cure of Gastrointestinal Cancers, several individuals in the cancer care community were honored for their efforts in improving the lives of patients with gastrointestinal cancers.
ASCO’s chief medical officer Richard L. Schilsky, MD, FACP, FASCO, is among the five gastrointestinal (GI) oncology professionals honored with OncLive® and The Ruesch Center for the Cure of Gastrointestinal Cancers’ 2018 Luminary Awards in GI Cancers.
Dr. Daniel D. Von Hoff, Distinguished Professor and Physician-In-Chief of the Translational Genomics Research Institute (TGen), an affiliate of the City of Hope, is one of five leading researchers who will receive a Luminary Award in GI Cancers from OncLive and The Ruesch Center for the Cure of Gastrointestinal Cancers.
The combination of the PD-L1 inhibitor atezolizumab (Tecentriq) and the VEGF inhibitor bevacizumab (Avastin) showed promising and durable antitumor activity in a phase Ib study of patients with advanced hepatocellular carcinoma (HCC).